208 related articles for article (PubMed ID: 20014119)
1. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
Rauen KA; Schoyer L; McCormick F; Lin AE; Allanson JE; Stevenson DA; Gripp KW; Neri G; Carey JC; Legius E; Tartaglia M; Schubbert S; Roberts AE; Gelb BD; Shannon K; Gutmann DH; McMahon M; Guerra C; Fagin JA; Yu B; Aoki Y; Neel BG; Balmain A; Drake RR; Nolan GP; Zenker M; Bollag G; Sebolt-Leopold J; Gibbs JB; Silva AJ; Patton EE; Viskochil DH; Kieran MW; Korf BR; Hagerman RJ; Packer RJ; Melese T
Am J Med Genet A; 2010 Jan; 152A(1):4-24. PubMed ID: 20014119
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.
Rauen KA; Huson SM; Burkitt-Wright E; Evans DG; Farschtschi S; Ferner RE; Gutmann DH; Hanemann CO; Kerr B; Legius E; Parada LF; Patton M; Peltonen J; Ratner N; Riccardi VM; van der Vaart T; Vikkula M; Viskochil DH; Zenker M; Upadhyaya M
Am J Med Genet A; 2015 Jan; 167A(1):1-10. PubMed ID: 25393061
[TBL] [Abstract][Full Text] [Related]
3. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
[TBL] [Abstract][Full Text] [Related]
4. The RASopathies.
Rauen KA
Annu Rev Genomics Hum Genet; 2013; 14():355-69. PubMed ID: 23875798
[TBL] [Abstract][Full Text] [Related]
5. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
Rauen KA; Alsaegh A; Ben-Shachar S; Berman Y; Blakeley J; Cordeiro I; Elgersma Y; Evans DG; Fisher MJ; Frayling IM; George J; Huson SM; Kerr B; Khire U; Korf B; Legius E; Messiaen L; van Minkelen R; Nampoothiri S; Ngeow J; Parada LF; Phadke S; Pillai A; Plotkin SR; Puri R; Raji A; Ramesh V; Ratner N; Shankar SP; Sharda S; Tambe A; Vikkula M; Widemann BC; Wolkenstein P; Upadhyaya M
Am J Med Genet A; 2019 Jun; 179(6):1091-1097. PubMed ID: 30908877
[TBL] [Abstract][Full Text] [Related]
6. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
7. A review of craniofacial and dental findings of the RASopathies.
Cao H; Alrejaye N; Klein OD; Goodwin AF; Oberoi S
Orthod Craniofac Res; 2017 Jun; 20 Suppl 1(Suppl 1):32-38. PubMed ID: 28643916
[TBL] [Abstract][Full Text] [Related]
8. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
[TBL] [Abstract][Full Text] [Related]
9. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
[TBL] [Abstract][Full Text] [Related]
10. RAS signalling in energy metabolism and rare human diseases.
Dard L; Bellance N; Lacombe D; Rossignol R
Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):845-867. PubMed ID: 29750912
[TBL] [Abstract][Full Text] [Related]
11. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
Bezniakow N; Gos M; Obersztyn E
Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
[TBL] [Abstract][Full Text] [Related]
12. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.
Fowlkes JL; Thrailkill KM; Bunn RC
Bone; 2021 Nov; 152():116060. PubMed ID: 34144233
[TBL] [Abstract][Full Text] [Related]
13. [New insight of craniofacial and oral findings of the RASopathies].
Cao HT; Yang YJ; Zheng Q; Shi B; Li CH
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Dec; 53(12):858-861. PubMed ID: 30522213
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of Growth Failure in Rasopathies.
Aftab S; Dattani MT
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):447-458. PubMed ID: 31115196
[TBL] [Abstract][Full Text] [Related]
16. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Tajan M; Paccoud R; Branka S; Edouard T; Yart A
Endocr Rev; 2018 Oct; 39(5):676-700. PubMed ID: 29924299
[TBL] [Abstract][Full Text] [Related]
17. Modeling RASopathies with Genetically Modified Mouse Models.
Hernández-Porras I; Guerra C
Methods Mol Biol; 2017; 1487():379-408. PubMed ID: 27924582
[TBL] [Abstract][Full Text] [Related]
18. RAS diseases in children.
Niemeyer CM
Haematologica; 2014 Nov; 99(11):1653-62. PubMed ID: 25420281
[TBL] [Abstract][Full Text] [Related]
19. Objective studies of the face of Noonan, Cardio-facio-cutaneous, and Costello syndromes: A comparison of three disorders of the Ras/MAPK signaling pathway.
Allanson JE
Am J Med Genet A; 2016 Oct; 170(10):2570-7. PubMed ID: 27155212
[TBL] [Abstract][Full Text] [Related]
20. RASopathies - what they reveal about RAS/MAPK signaling in skeletal muscle development.
Rauen KA; Tidyman WE
Dis Model Mech; 2024 Jun; 17(6):. PubMed ID: 38847227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]